Palo Alto Investors LP Grows Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Key Points

• Palo Alto Investors LP increased its stake in Taysha Gene Therapies by 75%, acquiring an additional 608,200 shares, bringing its total holdings to over 1.4 million shares, which constitutes 0.4% of its portfolio.
• Various analysts have endorsed Taysha Gene Therapies, with multiple firms raising their price targets and maintaining a consensus rating of "Buy", highlighting projected growth in the company's stock.
• Taysha Gene Therapies reported a loss of $0.09 per share for its latest quarter, falling short of estimates, but achieved revenue of $1.99 million, above the anticipated $1.61 million.

Palo Alto Investors LP raised its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 75.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,419,468 shares of the company's stock after purchasing an additional 608,200 shares during the quarter. Taysha Gene Therapies accounts for approximately 0.4% of Palo Alto Investors LP's investment portfolio, making the stock its 29th biggest holding. Palo Alto Investors LP owned 0.69% of Taysha Gene Therapies worth $1,973,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TSHA. Wells Fargo & Company MN lifted its stake in Taysha Gene Therapies by 43.7% in the 4th quarter. Wells Fargo & Company MN now owns 103,384 shares of the company's stock valued at $179,000 after buying an additional 31,457 shares in the last quarter. Barclays PLC increased its holdings in Taysha Gene Therapies by 35.6% in the 4th quarter. Barclays PLC now owns 335,238 shares of the company's stock valued at $587,000 after purchasing an additional 87,958 shares during the last quarter. Mariner LLC increased its holdings in Taysha Gene Therapies by 337.5% in the 4th quarter. Mariner LLC now owns 58,342 shares of the company's stock valued at $101,000 after purchasing an additional 45,006 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Taysha Gene Therapies by 268.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 51,085 shares of the company's stock valued at $88,000 after purchasing an additional 37,233 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its position in Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after buying an additional 8,076 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TSHA. Chardan Capital lifted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Needham & Company LLC restated a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. JMP Securities lifted their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Bank of America initiated coverage on shares of Taysha Gene Therapies in a research note on Friday, July 11th. They issued a "buy" rating and a $8.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of "Buy" and a consensus price target of $8.29.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded up $0.36 on Thursday, reaching $3.26. 14,217,441 shares of the stock were exchanged, compared to its average volume of 2,624,493. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.31. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average price of $2.71 and a two-hundred day moving average price of $2.24. The firm has a market capitalization of $889.33 million, a PE ratio of -9.59 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The firm had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. As a group, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.